TrialScientific reports2021
A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer.
Megumi Kai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this papertrialcites it